854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C.

Kingdon Capital Management L.L.C. bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 854,000 shares of the company’s stock, valued at approximately $8,361,000. Kingdon Capital Management L.L.C. owned 1.24% of Olema Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Deep Track Capital LP grew its holdings in shares of Olema Pharmaceuticals by 0.8% during the third quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after buying an additional 27,339 shares in the last quarter. Geode Capital Management LLC lifted its position in Olema Pharmaceuticals by 22.4% in the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after purchasing an additional 242,997 shares during the period. Candriam S.C.A. grew its position in Olema Pharmaceuticals by 46.9% in the third quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock valued at $12,235,000 after acquiring an additional 399,273 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Olema Pharmaceuticals by 193.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock worth $4,996,000 after acquiring an additional 773,064 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Olema Pharmaceuticals by 0.4% during the third quarter. Bank of America Corp DE now owns 802,304 shares of the company’s stock worth $7,855,000 after acquiring an additional 2,802 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $14.71 on Monday. The firm’s 50 day moving average is $24.18 and its 200-day moving average is $18.58. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.01 billion, a PE ratio of -7.87 and a beta of 1.93. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, March 17th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Naseem Zojwalla sold 99,509 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $27.66, for a total transaction of $2,752,418.94. Following the sale, the insider owned 4,488 shares of the company’s stock, valued at $124,138.08. This trade represents a 95.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the sale, the insider directly owned 139,727 shares in the company, valued at $4,014,356.71. The trade was a 41.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 805,501 shares of company stock valued at $23,003,832 over the last ninety days. 16.36% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on OLMA. HC Wainwright dropped their price target on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Oppenheimer reaffirmed an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. UBS Group started coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set a “buy” rating and a $45.00 target price for the company. TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Finally, The Goldman Sachs Group lifted their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.